Kiniksa Pharmaceuticals International, plc (KNSA)
NASDAQ: KNSA · Real-Time Price · USD
22.39
-0.71 (-3.05%)
Mar 31, 2025, 9:44 AM EDT - Market open

Company Description

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide.

Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an investigational, that is in Phase 2/3 clinical trial for human immunoglobulin G2 monoclonal antibody that binds human interleukin-1 receptor 1, inhibiting IL-1α, IL-1β-mediated signaling for the treatment of advance recurrent pericarditis by providing the added convenience of monthly subcutaneous dosing with a liquid formulation.

Its preclinical products include KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024.

The company was incorporated in 2015 and is based in London, the United Kingdom.

Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals International, logo
Country United Kingdom
Founded 2015
IPO Date May 24, 2018
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 315
CEO Sanj Patel

Contact Details

Address:
23 Old Bond Street, Floor 3
London, WIS 4PZ
United Kingdom
Phone 781 431 9100
Website kiniksa.com

Stock Details

Ticker Symbol KNSA
Exchange NASDAQ
Share Class Class A Shares
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001730430
CUSIP Number G5269C101
ISIN Number BMG5269C1010
SIC Code 2834

Key Executives

Name Position
Sanj K. Patel Chief Executive Officer and Chairman of the Board
Eben Tessari Senior Vice President and Chief Operating Officer
Dr. John F. Paolini FACC, M.D., Ph.D. Senior Vice President and Chief Medical Officer
Mark Ragosa C.F.A. Senior Vice President and Chief Financial Officer
Michael R. Megna CPA Chief Accounting Officer and Group Vice President of Finance
Mei Jang Senior Vice President of Technical Operations
Chad Morin Senior Vice President and Chief Compliance Officer
Madelyn Demsky Zeylikman SVice President, General Counsel and Secretary
Martina Struck Ph.D. Senior Vice President of Regulatory Affairs
Ross Moat Senior Vice President and Chief Commercial Officer

Latest SEC Filings

Date Type Title
Mar 17, 2025 144 Filing
Mar 12, 2025 144 Filing
Mar 12, 2025 144 Filing
Mar 10, 2025 144 Filing
Feb 25, 2025 S-8 Securities to be offered to employees in employee benefit plans
Feb 25, 2025 10-K Annual Report
Feb 25, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 10, 2025 144 Filing
Jan 13, 2025 144 Filing